Overview
Incyte
Incyte is a global biopharmaceutical company focused on the discovery, development, and commercialization of proprietary therapeutics. Its portfolio focuses on areas of high unmet medical need and includes compounds in various stages, ranging from preclinical to late-stage development, and commercialized products JAKAFI (ruxolitinib), ICLUSIG (ponatinib), PEMAZYRE (pemigatinib) and OPZELURA (ruxolitinib) cream, as well as MINJUVI (tafasitamab) and
...
Read More MONJUVI (tafasitamab-cxix), which are co-commercialized. In addition, its exclusive licensees sell its OLUMIANT and TABRECTA products.
Read Less
Read More MONJUVI (tafasitamab-cxix), which are co-commercialized. In addition, its exclusive licensees sell its OLUMIANT and TABRECTA products.
Read Less
#
747
Fortune 1000 Revenue Rank
Bill Meury
See more contacts
Scientific Research and Development Services
,
Professional, Scientific, and Technical Services
,
Commercial physical research
Accounting, Tax Preparation, Bookkeeping, and Payroll Services
,
Advertising, Public Relations, and Related Services
,
Architectural, Engineering, and Related Services
,
Computer Systems Design and Related Services
,
Legal Services
,
Management, Scientific, and Technical Consulting Services
,
Other Professional, Scientific, and Technical Services
,
Specialized Design Services
?
?
?
Modelled
?
Actual
$4.24 billion
Actual
14.76%
-94.54%
$5,444
DEC
?
?
NASDAQ:INCY
Contacts
Get in Touch with 5 Principals* and 946 Contacts
-
Bill MeuryChief Executive Officer
-
Contact 2?
-
Contact 3?
-
Contact 4?
Dynamic search and list-building capabilities
Real-time trigger alerts
Comprehensive company profiles
Valuable research and technology reports
Financial Statements
Dun & Bradstreet collects private company financials for more than 23 million companies worldwide. Find out more.
Financial data as of December 31, 2024 (12 month period) in USD
Annual Revenue 2024
$4.24 billion
USD
Actual
All financial statement data is in millions except per share data | Source: Morningstar
| Cash Flow (mil) | 2024 | 2023 | 2022 |
|---|---|---|---|
| Net Operating Cash | $335 | $496 | $970 |
| Net Investing Cash | $158 | -$208 | -$79 |
| Net Financing Cash | -$2,022 | -$20 | -$1 |
| Net Change in Cash | -$1,529 | $269 | $891 |
| Cash at Beginning of Period | $3,215 | $2,953 | $2,059 |
| Cash at End of Period | $1,689 | $3,215 | $2,953 |
| Capital Expenditure | -$100 | -$47 | -$78 |
| Assets (mil) | 2024 | 2023 | 2022 |
|---|---|---|---|
| Current Assets | |||
| Cash and Cash Equivalents | $1,688 | $3,213 | $2,951 |
| Accounts Receivable | $853 | $744 | $645 |
| Inventories | $59 | $63 | $42 |
| Other Current Assets | $639 | $625 | $455 |
| Asset Summary | |||
| Total Current Assets | $3,239 | $4,645 | $4,093 |
| Tangible Fixed Assets | $794 | $777 | $766 |
| Intangible Assets | $114 | $124 | $129 |
| Total Assets | $5,444 | $6,782 | $5,841 |
| Liabilities (mil) | 2024 | 2023 | 2022 |
|---|---|---|---|
| Current Liabilities | |||
| Accounts Payable | $197 | $110 | $278 |
| Short-Term Debt | $ | $ | $ |
| Other Current Liabilities | $1,444 | $1,131 | $880 |
| Liability Summary | |||
| Total Current Liabilities | $1,642 | $1,240 | $1,157 |
| Long-Term Debt | $ | $ | $ |
| Other Long-Term Liabilities | $321 | $323 | $284 |
| Total Liabilities | $1,997 | $1,592 | $1,471 |
| Stakeholder's Equity (mil) | 2024 | 2023 | 2022 |
|---|---|---|---|
| Equity | |||
| Common Stock | $0 | $0 | $0 |
| Retained Earnings | -$1,073 | $160 | -$437 |
| Equity Summary | |||
| Total Equity | $3,448 | $5,190 | $4,370 |
| Shares Outstanding | 193,434,305 | 224,286,862 | 222,746,719 |